Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

1.030 -0.020 (-1.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 214,712
Open 1.040
Bid (Size) 1.020 (200)
Ask (Size) 1.130 (1,700)
Prev. Close 1.050
Today's Range 1.010 - 1.050
52wk Range 0.8401 - 12.23
Shares Outstanding 11,586,406
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
From Tempest Therapeutics
Via GlobeNewswire

Performance

YTD
-65.1%
-65.1%
1 Month
+12.7%
+12.7%
3 Month
-18.9%
-18.9%
6 Month
-55.4%
-55.4%
1 Year
-89.7%
-89.7%

More News

Read More
News headline image
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026
From Tempest Therapeutics
Via GlobeNewswire
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill
News headline image
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Reports Year End 2025 Financial Results and Provides Business Update
From Tempest Therapeutics
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Tempest Therapeutics Announces Up To $6 Million Private Placement
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
From Tempest Therapeutics
Via GlobeNewswire
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
From Tempest Therapeutics
Via GlobeNewswire
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
From Tempest Therapeutics
Via GlobeNewswire
News headline image
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
From Tempest Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition
Via MarketMinute

Frequently Asked Questions

Is Tempest Therapeutics, Inc. - Common Stock publicly traded?
Yes, Tempest Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Tempest Therapeutics, Inc. - Common Stock trade on?
Tempest Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tempest Therapeutics, Inc. - Common Stock?
The ticker symbol for Tempest Therapeutics, Inc. - Common Stock is TPST on the Nasdaq Stock Market
What is the current price of Tempest Therapeutics, Inc. - Common Stock?
The current price of Tempest Therapeutics, Inc. - Common Stock is 1.030
When was Tempest Therapeutics, Inc. - Common Stock last traded?
The last trade of Tempest Therapeutics, Inc. - Common Stock was at 09/04/26 04:00 PM ET
What is the market capitalization of Tempest Therapeutics, Inc. - Common Stock?
The market capitalization of Tempest Therapeutics, Inc. - Common Stock is 11.93M
How many shares of Tempest Therapeutics, Inc. - Common Stock are outstanding?
Tempest Therapeutics, Inc. - Common Stock has 12M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.